CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code

Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has shown promising results in preclinical and clinical studies, granting its conditional approval by the FDA in May 2021. The phase I clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shannon S, Lee, Alexandria, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123019/
https://www.ncbi.nlm.nih.gov/pubmed/37101895
http://dx.doi.org/10.2147/LCTT.S403461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123019/
https://www.ncbi.nlm.nih.gov/pubmed/37101895
http://dx.doi.org/10.2147/LCTT.S403461

Ejemplares similares